Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund grew its position in Hologic, Inc. (NASDAQ:HOLX) by 13.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 177,633 shares of the medical equipment provider’s stock after purchasing an additional 21,644 shares during the quarter. Illinois Municipal Retirement Fund owned approximately 0.08% of Hologic worth $12,806,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. RWC Asset Management LLP raised its holdings in shares of Hologic by 13.0% in the 4th quarter. RWC Asset Management LLP now owns 2,971 shares of the medical equipment provider’s stock valued at $214,000 after purchasing an additional 342 shares in the last quarter. Capital Investment Counsel Inc grew its position in shares of Hologic by 3.6% in the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock valued at $413,000 after buying an additional 200 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of Hologic by 8.2% in the 4th quarter. Handelsbanken Fonder AB now owns 214,233 shares of the medical equipment provider’s stock valued at $15,444,000 after buying an additional 16,262 shares during the last quarter. Private Advisor Group LLC grew its position in shares of Hologic by 7.7% in the 4th quarter. Private Advisor Group LLC now owns 17,931 shares of the medical equipment provider’s stock valued at $1,293,000 after buying an additional 1,278 shares during the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Hologic by 15.5% in the 4th quarter. Global Retirement Partners LLC now owns 2,175 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 292 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Up 0.3 %

Shares of NASDAQ:HOLX opened at $65.23 on Wednesday. The company has a market cap of $14.64 billion, a price-to-earnings ratio of 20.58, a PEG ratio of 2.14 and a beta of 0.98. The firm’s 50-day simple moving average is $69.62 and its 200-day simple moving average is $76.28. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.88% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent analyst reports. Evercore ISI dropped their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Mizuho dropped their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Stephens reaffirmed an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Finally, Jefferies Financial Group began coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. Ten analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.